Balsalazide

Drugs

Volumn 56, Issue 1, 1998, Pages 83-89

  Prakash, A ^a   Spencer, C M ^a  

^a International Limited   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BALSALAZIDE; DRUG CARRIER; MESALAZINE; PRODRUG; PROSTAGLANDIN;

AREA UNDER THE CURVE; CLINICAL TRIAL; CROHN DISEASE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FLATULENCE; HEADACHE; HUMAN; INTESTINE MUCOSA; ORAL DRUG ADMINISTRATION; REMISSION; REVIEW; ULCERATIVE COLITIS;

EID: 0031876405     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856010-00008     Document Type: Review

References (25)

1. 1. A Kornbluth DB Sachar 1997 Ulcerative colitis practice guidelines in adults Am J Gastroenterol 92 2 204 11 9040192 1:STN:280:DyaK2s7pt1Kjsg%3D%3D Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. Am J Gastroenterol 1997; 92(2): 204–11
2. 2. McCombs CC, deShazo RD. Immune system disorders. In: Speight TM, Holford NHG, editors. Avery’s drug treatment. 4th ed. Auckland: Adis International Limited, 1997: 1294–345
3. 3. RP Chan DJ Pope AP Gilbert 1983 Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide Dig Dis Sci 28 609 15 6345112 10.1007/BF01299921 1:CAS:528:DyaL3sXls12gsrw%3D Chan RP, Pope DJ, Gilbert AP, et al. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci 1983 Jul; 28: 609–15
4. 4. DS Levine R Pruitt D Riff 1997 A multi-center, double-blind dose-response trial of Colazide® (balsalazide disodium) and Asacol® (mesalamine) for mild-moderately active ulcerative colitis [abstract] Gastroenterology 112 1026 Levine DS, Pruitt R, Riff D, et al. A multi-center, double-blind dose-response trial of Colazide® (balsalazide disodium) and Asacol® (mesalamine) for mild-moderately active ulcerative colitis [abstract]. Gastroenterology 1997 Apr; 112 Suppl.: 1026
5. 5. SPL Travis DP Jewell 1994 Salicylates for ulcerative colitis — Their mode of action Pharmacol Ther 63 2 135 61 7809176 10.1016/0163-7258(94)90042-6 1:CAS:528:DyaK2cXlvFCkt7s%3D Travis SPL, Jewell DP. Salicylates for ulcerative colitis — Their mode of action. Pharmacol Ther 1994; 63(2): 135–61
6. 6. NJ Simmonds DR Blake DS Rampton 1992 The effect of amino-salicylates and potential new drugs on mucosal reactive oxygen metabolite production in ulcerative colitis [abstract] Gut 1 7 Simmonds NJ, Blake DR, Rampton DS. The effect of amino-salicylates and potential new drugs on mucosal reactive oxygen metabolite production in ulcerative colitis [abstract]. Gut 1992; 33 Suppl. 1: 7
7. 7. Riddell JG, Bell D, Hendy C. A comparative tolerability and pharmacokinetic study of balsalazide disodium (colazide®), sulphasalazine (salazopyrin®) and mesalazine (asacol®) following a single oral dose. Glycyx Pharmaceuticals Limited. Harris Project No. 20060; 1998 (Data on file)
8. 8. Green JRB, Gibson JA, Brown P, et al. Pharmacokinetic study of balsalazide disodium (colazide®) in patients with ulcerative colitis receiving long term maintenance therapy. Glycyx Pharmaceuticals Limited. GLY 01/93; 1998 (Data on file)
9. 9. JRB Green CD Holdsworth AJ Lobo 1998 Balsalazide is more effective and better tolerated than mesalamine in acute ulcerative colitis Gastroenterology 114 15 22 9428213 10.1016/S0016-5085(98)70627-4 1:CAS:528:DyaK1cXksFyrtA%3D%3D Green JRB, Holdsworth CD, Lobo AJ, et al. Balsalazide is more effective and better tolerated than mesalamine in acute ulcerative colitis. Gastroenterology 1998; 114: 15–22
10. 10. JRB Green CHJ Swan AE Rowlinson 1993 Sulphasalazine or high dose balsalazide to treat acute relapse in ulcerative colitis? Results of a randomized trial [abstract] Gastroenterology 104 A709 Green JRB, Swan CHJ, Rowlinson AE, et al. Sulphasalazine or high dose balsalazide to treat acute relapse in ulcerative colitis? Results of a randomized trial [abstract]. Gastroenterology 1993 Apr; 104 Suppl.: A709
11. 11. JC Mansfield MH Giaffer PA Cann 1991 Is high dose balsalazide better than sulphasalazine in initial management of ulcerative colitis ? [abstract] Gut 32 1217 Mansfield JC, Giaffer MH, Cann PA, et al. Is high dose balsalazide better than sulphasalazine in initial management of ulcerative colitis ? [abstract]. Gut 1991 Oct; 32: 1217
12. 12. MH Giaffer CD Holdsworth JE Lennard-Jones 1992 Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day Aliment Pharmacol Ther 6 479 85 1358234 10.1111/j.1365-2036.1992.tb00561.x 1:STN:280:DyaK3s%2Fkt1CrtQ%3D%3D Giaffer MH, Holdsworth CD, Lennard-Jones JE, et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Aliment Pharmacol Ther 1992 Aug; 6: 479–85
13. 13. PB McIntyre CA Rodrigues JE Lennard-Jones 1988 Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine Aliment Pharmacol Ther 2 237 43 2908755 10.1111/j.1365-2036.1988.tb00693.x 1:STN:280:DyaK38%2Fjt1eguw%3D%3D McIntyre PB, Rodrigues CA, Lennard-Jones JE, et al. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Aliment Pharmacol Ther 1988 Jun; 2: 237–43
14. 14. JR Green CH Swan A Rowlinson 1992 Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months Aliment Pharmacol Ther 6 647 52 1420754 10.1111/j.1365-2036.1992.tb00578.x 1:STN:280:DyaK3s%2Fkt1Gjtg%3D%3D Green JR, Swan CH, Rowlinson A, et al. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Aliment Pharmacol Ther 1992 Oct; 6: 647–52
15. 15. JRB Green CHJ Swan AE Rowlinson 1991 Maintenance of remission in ulcerative colitis by 2-dose levels of balsalazide — results of a 2 year double-blind cross-over study [abstract] Ital J Gastroenterol 23 645 Green JRB, Swan CHJ, Rowlinson AE, et al. Maintenance of remission in ulcerative colitis by 2-dose levels of balsalazide — results of a 2 year double-blind cross-over study [abstract]. Ital J Gastroenterol 1991 Dec; 23: 645
16. 16. JRB Green CHJ Swan AE Rowlinson 1992 A three-year prospective study of the maintenance of remission of ulcerative colitis by a new 5ASA-releasing agent, balsalazide [abstract] Gastroenterology 102 A631 Green JRB, Swan CHJ, Rowlinson AE, et al. A three-year prospective study of the maintenance of remission of ulcerative colitis by a new 5ASA-releasing agent, balsalazide [abstract]. Gastroenterology 1992 Apr; 102 (Pt 2): A631
17. 17. JRB Green CHJ Swan AE Rowlinson 1994 The natural history of ulcerative colitis treated with balsalazide sodium over four years [abstract] Gastroenterology 106 692 Green JRB, Swan CHJ, Rowlinson AE, et al. The natural history of ulcerative colitis treated with balsalazide sodium over four years [abstract]. Gastroenterology 1994 Apr; 106 Suppl.: 692
18. 18. Kruis W, The German colazide study group. A comparison of two different doses of balsalazide and one dose of mesalazine in chronic treatment of ulcerative colitis [abstract]. Gastroenterology 1998; (In press)
19. 19. Green JRB, Gibson JA, Kerr GD, et al. Maintenance treatment with balsalazide provides more effective control of nocturnal symptoms of ulcerative colitis (UC) than delayed-release mesalazine [abstract]. Gastroenterology 1998; (In press)
20. 20. Overall incidence of adverse events in maintenance colazide® studies. Colazide® (balsalazide disodium) capsules. Integrated summary of safety. Astra Draco AB, (Lund). NDA20-610. 1998 (Data on file)
21. 21. Overall incidence of adverse events in controlled acute studies. Colazide® (balsalazide disodium) capsules. Integrated summary of safety. Astra Draco AB (Lund). NDA20-610. 1998 (Data on file)
22. 22. JRB Green CHJ Swan AE Rowlinson 1991 High dose balsalazide compared with sulphasalazine in the treatment of acute relapse in ulcerative colitis [abstract] Gut 32 1217 Green JRB, Swan CHJ, Rowlinson AE, et al. High dose balsalazide compared with sulphasalazine in the treatment of acute relapse in ulcerative colitis [abstract]. Gut 1991 Oct; 32: 1217
23. 23. Green JRB, Swan CHJ, Rowlinson AE, et al. High dose balsalazide sodium or sulphasalazine as therapy for acute relapse in ulcerative colitis? Results of a double-blind, randomised trial [abstract]. In: 10th World Congress of Gastroenterology: 1994 Oct 2–7; Los Angeles (Cal).:, 1994: 1773P
24. 24. MH Giaffer CJ O’Brien CD Holdsworth 1992 Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine Aliment Pharmacol Ther 6 51 9 1347468 10.1111/j.1365-2036.1992.tb00544.x 1:STN:280:DyaK387ot1Wnug%3D%3D Giaffer MH, O’Brien CJ, Holdsworth CD. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Aliment Pharmacol Ther 1992 Feb; 6: 51–9
25. 25. PB McIntyre JE Lennard-Jones 1984 Reversal with balsalazide of infertility caused by sulphasalazine Br Med J 288 1652 3 10.1136/bmj.288.6431.1652-a 1:STN:280:DyaL2c3gsVKnsg%3D%3D McIntyre PB, Lennard-Jones JE. Reversal with balsalazide of infertility caused by sulphasalazine. Br Med J 1984 Jun 2; 288: 1652–3